Jiří Mayer

1.9k total citations · 1 hit paper
48 papers, 1.0k citations indexed

About

Jiří Mayer is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Jiří Mayer has authored 48 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 22 papers in Hematology and 14 papers in Oncology. Recurrent topics in Jiří Mayer's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Jiří Mayer is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Jiří Mayer collaborates with scholars based in Czechia, United States and Germany. Jiří Mayer's co-authors include Andreas Hochhaus, Michele Baccarani, Juan Luis Steegmann, Jörge E. Cortes, Dong‐Wook Kim, M. Brigid Bradley‐Garelik, Mark Wildgust, Giuseppe Saglio, Concepción Boqué and Carolina Pavlovsky and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jiří Mayer

41 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

2016 330 citations Juan Luis Steegmann, Michele Baccarani et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jiří Mayer Czechia	11	748	679	320	162	161	48	1.0k
Jesper Stentoft Denmark	16	780 1.0×	534 0.8×	283 0.9×	158 1.0×	208 1.3×	52	974
Anna Turkina Russia	17	1.2k 1.6×	1.0k 1.5×	544 1.7×	234 1.4×	296 1.8×	134	1.5k
Serena Merante Italy	17	554 0.7×	492 0.7×	342 1.1×	131 0.8×	80 0.5×	40	828
Nathalie Cambier France	14	615 0.8×	725 1.1×	297 0.9×	385 2.4×	235 1.5×	41	1.1k
Joanna Góra‐Tybor Poland	18	594 0.8×	733 1.1×	186 0.6×	291 1.8×	218 1.4×	82	1.2k
Laurie Letvak United States	14	749 1.0×	566 0.8×	514 1.6×	114 0.7×	144 0.9×	31	981
Jean Michel Cayuela France	10	481 0.6×	411 0.6×	245 0.8×	132 0.8×	149 0.9×	12	727
Isamu Sugiura Japan	17	905 1.2×	293 0.4×	163 0.5×	172 1.1×	187 1.2×	80	1.2k
Stéphanie Harel France	15	315 0.4×	276 0.4×	91 0.3×	316 2.0×	190 1.2×	51	785
Eri Kawata Japan	14	455 0.6×	327 0.5×	177 0.6×	279 1.7×	188 1.2×	42	842

Countries citing papers authored by Jiří Mayer

Since Specialization

Citations

This map shows the geographic impact of Jiří Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiří Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiří Mayer more than expected).

Fields of papers citing papers by Jiří Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiří Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiří Mayer. The network helps show where Jiří Mayer may publish in the future.

Co-authorship network of co-authors of Jiří Mayer

This figure shows the co-authorship network connecting the top 25 collaborators of Jiří Mayer. A scholar is included among the top collaborators of Jiří Mayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiří Mayer. Jiří Mayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Issa, Ghayas C., Andreas Hochhaus, Timothy P. Hughes, et al.. (2025). CML-754: Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis. Clinical Lymphoma Myeloma & Leukemia. 25. S575–S576.

Lehr, L., et al.. (2025). Potential of digital technologies in counteracting long-standing deficits in hemodialysis machine training. Scientific Reports. 15(1). 5562–5562.

Vojtová, Lucy, et al.. (2025). Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation. Molecular Oncology. 19(5). 1371–1385. 1 indexed citations

Hughes, Timothy P., Andreas Hochhaus, Naoto Takahashi, et al.. (2024). ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.. Journal of Clinical Oncology. 42(17_suppl). LBA6500–LBA6500. 2 indexed citations

Oh, Stephen T., Srđan Verstovšek, Vikas Gupta, et al.. (2024). Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. SHILAP Revista de lepidopterología. 5(1). 105–116. 12 indexed citations

Cortes, Jörge E., Andreas Hochhaus, Timothy P. Hughes, et al.. (2024). Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study. Blood. 144(Supplement 1). 475–475. 3 indexed citations

Pettit, Kristen, Joseph J. Shatzel, Abdulraheem Yacoub, et al.. (2024). VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).. Journal of Clinical Oncology. 42(16_suppl). TPS6592–TPS6592. 1 indexed citations

Weinbergerová, Barbora, Jiří Mayer, Wolfgang R. Sperr, et al.. (2024). Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis. British Journal of Haematology. 205(5). 1746–1750. 2 indexed citations

Gupta, Vikas, Stephen T. Oh, Timothy Devos, et al.. (2023). POSTER: MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1. Clinical Lymphoma Myeloma & Leukemia. 23. S192–S192. 1 indexed citations

10.

Ando, Kiyoshi, Laimonas Griškevičius, Takayuki Ikezoe, et al.. (2023). P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI-C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI). HemaSphere. 7(S3). e17022e8–e17022e8. 1 indexed citations

11.

Zinzani, Pier Luigi, Jiří Mayer, Ohad Benjamini, et al.. (2023). waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.. Journal of Clinical Oncology. 41(16_suppl). TPS7595–TPS7595. 2 indexed citations

12.

Platzbecker, Uwe, Argiris Symeonidis, Esther Natalie Olíva, et al.. (2017). A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 31(9). 1944–1950. 84 indexed citations

13.

Steegmann, Juan Luis, Michele Baccarani, Massimo Breccia, et al.. (2016). European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 30(8). 1648–1671. 330 indexed citations breakdown →

14.

Kaucká, Markéta, Karla Plevová, Šárka Pavlová, et al.. (2013). The Planar Cell Polarity Pathway Drives Pathogenesis of Chronic Lymphocytic Leukemia by the Regulation of B-Lymphocyte Migration. Cancer Research. 73(5). 1491–1501. 82 indexed citations

15.

Plevová, Karla, Hana Skuhrová Francová, Yvona Brychtová, et al.. (2013). Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. Haematologica. 99(2). 329–338. 30 indexed citations

16.

Pfeiffer, Tim, Michael Schleuning, Jiří Mayer, et al.. (2012). Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematologica. 98(4). 518–525. 21 indexed citations

17.

Szturz, Petr, Zdeněk Adam, Roman Hájek, & Jiří Mayer. (2011). Successful Anakinra Therapy in 2 Patients with Schnitzler Syndrome. Onkologie. 34(5). 265–268. 5 indexed citations

18.

Adam, Zdeněk, Zdeněk Řehák, Petr Szturz, et al.. (2011). [Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review].. PubMed. 57(6). 576–89. 11 indexed citations

19.

Panovský, Roman, Jaroslav Meluzı́n, Stanislav Janoušek, et al.. (2008). Cell Therapy in Patients with Left Ventricular Dysfunction Due to Myocardial Infarction. Echocardiography. 25(8). 888–897. 15 indexed citations

20.

Mayer, Jiří, Michael Doubek, & Jiří Vorlíček. (1999). Must we really fear toxicity of conventional amphotericin B in oncological patients?. Supportive Care in Cancer. 7(1). 51–51. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact